The auto-injector market is estimated to grow at a CAGR of

Pune, 24th Nov, 2022 (GLOBE NEWSWIRE) — According to a new market research report titled: “Autoinjector Market by product type (disposable auto-injectors, reusable auto-injectors), by disease indication (rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, others) and by end user (hospitals, home care, others) – Global Outlook and Forecasts 2022-2030″ published by Growth Plus Reports, the market for autoinjectors is expected to grow at a rate CAGR of 16.60% from 2021 to arrive US$191.21 billion by 2030.

Download sample PDF brochure from Autoinjector Market🇧🇷

https://growthplusreports.com/inquiry/request-sample/auto-injectors-market/7925

market driver

The increase in demand for targeted therapies and self-administration is the main driver of the global auto-injector market. Furthermore, the rising incidence of anaphylaxis, migraines and chronic diseases such as diabetes, rheumatoid arthritis and multiple sclerosis is also a major driver of the global auto-injector market. Auto-injectors have several advantages, including improved quality and efficacy of dosing, decreased needle phobia, fewer needlestick injuries and accidents, and greater dosing accuracy. Increased research and development of biologics, as well as increasing approval of biologics and biosimilars, is facilitating the growth of the autoinjector market. The adoption of cutting-edge technologies, the expiration of patents on biologics, and increased investment from market leaders to manufacture affordable, reusable injectors are expected to drive market growth.

The global autoinjector market was analyzed from three perspectives: product type, disease indication, end user and region.

excerpts from ‘Segmentation by product type’

On the basis of product type, the global autoinjector market is divided into

  • Disposable
  • reusable auto-injectors

Disposable autoinjectors hold the highest market share in 2021. The large share of disposable autoinjectors is mainly attributed to their ease of use. They have a built-in syringe, which eliminates the need for manual loading of the syringe and thus increases device safety. Biopharmaceutical companies are investing in advanced technologies to improve disposable autoinjectors. For example, in March 2022, Ipsen announced investment in a new state-of-the-art electronic autoinjector for Somatuline, Autogel / Somatuline Depot (lanreotide), to bring additional innovation to the class to improve the administration and injection experience for patients. . This device will be made in collaboration with Phillips-Medisize.

Excerpts from ‘By Disease Indication Segmentation’

On the basis of disease indications, the global autoinjectors market is segmented into

  • Rheumatoid arthritis
  • Multiple sclerosis
  • Diabetes
  • anaphylaxis
  • Other therapies

Anaphylaxis segment dominates the market with the highest market share in 2021. Diabetes is another important application area for autoinjectors. The segment is growing due to the increased demand for insulin auto-injectors. According to the International Diabetes Federation, type 1 diabetes affects approximately 10% of the population with diabetes, with approximately 1.2 million children and adolescents affected. In addition, the demand for self-administered insulin in home care is also driving growth in the segment.

Excerpts from ‘Region targeting’

On the basis of region, the global auto-injector market has been classified into

  • North America
  • Europe
  • Asia Pacific
  • The rest of the world

North America dominated the global market for autoinjectors in 2021. Europe has the second largest market for autoinjectors. The large share of the market can be attributed to the increasing prevalence of anaphylaxis and chronic diseases such as diabetes, rheumatoid arthritis and multiple sclerosis. According to the European Academy of Allergy and Clinical Immunology (EAACI), more than 150 million people in Europe suffer from chronic allergic diseases. In the UK, around 20% of the population has allergies. According to the MRC Asthma UK Center in Allergic Mechanisms of Asthma, approximately 20 to 30 deaths are caused by allergies in the UK.

Excerpts from ‘Competitive Scenario’

Some of the key players operating in the global Automotive Injectors market are

  • Mylan NV
  • Abvie Inc.
  • Eli Lilly And Company
  • Amgen Inc.
  • Becton, Dickinson and Company
  • Ypsomed Holding AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Merck Kgaa
  • Owen Mumford
  • Halozyme Therapeutics
  • Glaxosmithkline Plc
  • Biogen Inc.
  • Sanofi SA
  • Scandinavian Health Ltd.

Inform yourself before purchasing this research report:

https://growthplusreports.com/inquiry/before-buying/auto-injectors-market/7925

Index

  1. INTRODUCTION
    1. market ecosystem
    2. Timeline under consideration
      1. Historic years – 2020
      2. Base year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY
    1. research approach
    2. Data Collection Methodology
    3. data sources
      1. secondary sources
      2. primary sources
    4. Market estimation approach
      1. Bottom up
      2. Bald
    5. Market Forecast Model
    6. Limitations and Assumptions
  3. PREMIUM INFORMATION
    1. Current Market Trends (COVID-19 Perspective)
    2. Key players and competitive positioning (2021)
  4. MARKET DYNAMICS
    1. drivers
    2. Restrictions/Challenges
    3. opportunities
  5. GLOBAL MARKET AUTO-INJECTORS – ANALYSIS AND FORECAST, BY TYPE OF PRODUCT
    1. disposable auto-injectors
    2. reusable auto-injectors
      1. pre-populated
      2. Empty
  6. GLOBAL MARKET OF AUTOINJECTORS – ANALYSIS AND FORECAST, BY DISEASE INDICATION
    1. Rheumatoid arthritis
    2. Multiple sclerosis
    3. Diabetes
    4. anaphylaxis
    5. Other therapies
  7. GLOBAL AUTO-INJECTORS MARKET – ANALYSIS AND FORECAST, BY END USERS
    1. hospitals
    2. home care
    3. Others (Outpatient Surgical Centers, Nurseries, etc.)

OCD Continue…

Report Scope:

report attributeDetails
Market size value in 2021$48 billion
Revenue forecast in 2030$191.21 billion
Growth rateCAGR of 16.60% from 2022 to 2030
Base year for estimation2021
forecast period2022-2030
covered segmentsProduct type, disease indication, end user and region.
regional scopeNorth America, Europe, Asia Pacific and Rest of the World (ROW)

VALUE PROPOSALS RELATED TO THE REPORT:

  • Built with hours of complimentary analysis and expert interviews on every report
  • Comprehensive quantitative and qualitative insights at the segment and sub-segment level
  • Trends and perspective of the impact of Covid 19
  • Granular insights at global/regional/country level
  • Deep-rooted insights into market dynamics (drivers, constraints, opportunities) and business environment
  • General coverage in the competitive landscape
  • winning imperatives
  • Exhaustive coverage of ‘Strategic Developments’ recorded by major market players

CUSTOMIZATION OPTIONS🇧🇷

  • Distributor scenario assessment
  • Pipeline Assessment
  • price intelligence
  • Customer Base Assessment
  • Analysis of Investments and Initiatives
  • ‘Business profile’ of key players

Quickly purchase a Premium copy of Autoinjector Market Report:

https://growthplusreports.com/checkout?_token=6Xf4OeYdDWa1ST0hqICMhoa5w0EwLgoboL1z8BOz&report_id=7925&license=Single

About Us

Growth Plus Reports is part of GRG Health, a global health knowledge services company. We are proud to be members of the EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth+ portfolio of services draws on our core capabilities of secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and innovative solutions that set them up for growth and future success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

The auto-injector market is estimated to grow at a CAGR of

Leave a Reply

Your email address will not be published.

Scroll to top